About Tango Therapeutics
Tango Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2017. It operates as a novel cancer drugs are developed using synthetic lethality screening. Tango Therapeutics has raised $165 million across 5 funding rounds from investors including Gilead, Casdin Capital and Boxer Capital. The company has 155 employees. Its chief executive is Barbara Weber. Its website tangotx.com draws about 17 thousand monthly visits. Tango Therapeutics offers products and services including PRMT5 Program and CoREST Program. Its focus areas include Life Sciences, Genomics, Genomics Research and Biomarker Discovery. Its competitors include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen and 2 more; 7 of its 7 listed competitors have raised funding.
Company details
Tango Therapeutics was founded in 2017 in Cambridge, United States, as a biotechnology firm focused on oncology. Precision therapies are created by identifying genetic vulnerabilities in tumor suppressor genes through DNA sequencing and CRISPR-based functional screens. Targets are selected for specific patient subgroups, exploiting synthetic lethality to induce tumor cell death while sparing healthy cells. Operations center on early-stage drug discovery in the precision medicine sector.
- Headquarters Cambridge, United States
- Employees 155
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website tangotx.com
- Social LinkedIn
- Legal Name Tango Therapeutics, Inc.
- Annual Revenue$62.38 M (USD)48.29as on Dec 31, 2025
- Net Profit-$101.59 M (USD)22.03as on Dec 31, 2025
- EBITDA-$109.01 M (USD)23.82as on Dec 31, 2025
- Total Equity Funding$165M (USD)
in 5 rounds
- Latest Funding Round$15M (USD), Post-IPO
Oct 2025
- InvestorsGilead
& 4 more
- Employee Count155
Products & Services of Tango Therapeutics
Tango Therapeutics offers a comprehensive portfolio of products and services, including PRMT5 Program and CoREST Program.
Targets tumors using synthetic lethality for precision medicine.
Develops targeted therapies for cancer treatment approaches.
Funding Insights of Tango Therapeutics
Tango Therapeutics has successfully raised a total of $165M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $165M
- Total Rounds 5
- Last Round Post-IPO — $15M
- First Round $55M
(Mar 2017)
- Investors Count 5
All 5 funding rounds of Tango Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $15M | Post-IPO | – | – | – |
| Aug 2023 | $80M | Post-IPO | – | – | – |
| Aug 2020 | $50M | Series B | – | Casdin Capital | |
| Apr 2020 | $60M | Series B | – | Boxer Capital | |
| Mar 2017 | $55M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Tango Therapeutics
Tango Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Casdin Capital and Boxer Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
Tavistock Group is engaged in global diversified investments. | – | tavistock.com | - | |
Venture capital funding is provided to early-stage life science companies. | – | thirdrockventures.com | Boston, United States | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States |
Investor details for Tango Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tango Therapeutics
99 people are tracked at Tango Therapeutics (56 in leadership, 11 in board & advisors, 32 in team); the tracked headcount is 155.
| Name | Role | Group |
|---|---|---|
Barbara Weber | CEO & President | Leadership |
Adam Crystal | President, Research & Development | Leadership |
Eric Robertson | Director, Clinical Compliance | Leadership |
Laurie Callen | Vice President, Biometrics | Leadership |
Maxim Pimkin | Senior Director, Clinical Development | Leadership |
Heather Dibenedetto | VP of Development Operations | Leadership |
Daniella Beckman | Chief Financial Officer | Leadership |
Hongming Li | Director, Process Chemistry, CMC | Leadership |
Jon Come | Senior Director | Leadership |
Abi O'Hare | Head Of Talent Acquisition | Leadership |
Elizabeth Hickin | Vp, Investor Relations And Corporate Communications | Leadership |
Leanne Ahronian | Associate Director | Leadership |
Sandra Sutera | Vp, Head Of Program & Portfolio Management, Chief Of Staff To The President Of R&d | Leadership |
Katie Woolford | Associate Director Clinical Operations | Leadership |
Jen Morawiak | Director, Clinical Trials | Leadership |
Donna Fitzgerald | Director, Clinical Sciences | Leadership |
Jannik N. Andersen | Chief Scientific Officer | Leadership |
Michael Palmieri | Head of Chemistry, Manufacturing, & Controls | Leadership |
William Mallender | VP of Biochemistry | Leadership |
Sean Hetherman | Senior Director, Corporate Controller | Leadership |
79 more people are available in the full profile.
Complete people profiles for Tango Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tango Therapeutics
Tango Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TNGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Apr 2021
- Listed onNASDAQ: TNGX
- Listed entityTango Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS87583X1090
- Share price$22.22 (-8.07% on the day) · 2026-10-13
- Market capitalisation$3.75B
- EPS (diluted, trailing year)$-0.84
- Volume (last session)9,619,155
Financials of Tango Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $62.4M | -$101.6M | -$109.0M |
| 2024 | $42.1M | -$130.3M | -$143.1M |
| 2023 | $36.5M | -$101.7M | -$111.8M |
| 2022 | $24.9M | -$108.2M | -$107.0M |
| 2021 | $37.0M | -$58.2M | -$56.2M |
Detailed financial statements for Tango Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Tango Therapeutics
4 dated milestones of Tango Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Tango Therapeutics is founded.
- Funding First funding round of $55.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
Competitors of Tango Therapeutics
Tango Therapeutics has 7 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Tango Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tango Therapeutics
The website of Tango Therapeutics (tangotx.com) receives about 16.5K visits a month and ranks #1,726,028 among all websites worldwide, #2,338 in Biotechnology and Pharmaceuticals.
- Monthly visits16.5K
▲ 61% vs previous month
- Unique visitors4K
per month
- Global rank#1,726,028
among all websites
- Category rank#2,338
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit3.7
- Average visit3 min 35 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with Tango Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biopharmadive.com | 100% | 680.7K | #208,628 | View details | |
| oncologypipeline.com | 100% | 76.4K | #510,302 | View details | |
ispor.org | ispor.org | 60% | – | #299,577 | – |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Tango Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tango Therapeutics
Complete news archive for Tango Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tango Therapeutics
Tango Therapeutics was founded in 2017.
Tango Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Barbara Weber is the current CEO of Tango Therapeutics.
Tango Therapeutics is a funded company, having raised a total of $165M across 5 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Mar 2017.
Tango Therapeutics has 155 employees.
Annual revenue of Tango Therapeutics is $62.38M as on Dec 31, 2025.
Tango Therapeutics was founded in 2017 in Cambridge, United States, as a biotechnology firm focused on oncology. Precision therapies are created by identifying genetic vulnerabilities in tumor suppressor genes through DNA sequencing and CRISPR-based functional screens. Targets are selected for specific patient subgroups, exploiting synthetic lethality to induce tumor cell death while sparing healthy cells. Operations center on early-stage drug discovery in the precision medicine sector.
Tango Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Tango Therapeutics offers PRMT5 Program and CoREST Program.
Yes, Tango Therapeutics is publicly traded on NASDAQ under the ticker symbol TNGX.
Tango Therapeutics has 5 investors. Key investors include Gilead, Casdin Capital, Boxer Capital, Tavistock Group, and Third Rock Ventures.